

Differential cognitive impairment in HCV coinfecting men with controlled HIV compared to HCV mono-infection

Bing Sun, M.D., Ph.D.¹, Linda Abadjian PhD², Hans Rempel¹, PhD, Alexander Monto, MD³,

Lynn Pulliam, MS, Ph.D.^{1,4}

¹Department of Laboratory Medicine, Veterans Affairs Medical Center, San Francisco, CA

²Department of Mental Health, Veterans Affairs Medical Center, San Francisco, CA

³Department of Medicine, Division of Gastroenterology, Veterans Affairs Medical Center and University of California, San Francisco, CA

⁴Department of Laboratory Medicine, University of California, San Francisco, CA

Corresponding Author:

Lynn Pulliam, MS, PhD

Veterans Affairs Medical Center

Department of Laboratory Medicine

4150 Clement St (113A)

San Francisco, CA 94121

Tel: 415-221-4810 X6490

FAX: 415-379-5647

Email: lynn.pulliam@ucsf.edu

Conflicts of Interest and source of Funding:

No authors have any conflicts of interest to declare

This study was supported by NIMH RO1MH085538 (LP)

Running Head: Neurocognitive decline in HIV/HCV infection

Background: Individuals infected with both HIV and HCV have shown impaired performance on different neuropsychological (NP) tests; however, whether coinfecting individuals with controlled HIV and minimal liver damage in the era of antiretroviral therapy have impairment is understudied.

Methods: Nineteen HCV monoinfected, 17 HIV/HCV coinfecting and 17 control male participants were evaluated for depression, attention, executive function, information processing, fine motor speed, and verbal/visual learning/memory. Eleven controls and 14 HIV monoinfected participants with controlled viral load from a previous study were also included for comparison. At time of testing, participants were not using drugs or alcohol and did not have cirrhosis. A global deficit score (GDS) was calculated from 7 domains of NP tests and alterations in specific domains were determined.

Results: HIV/HCV subjects had a higher depression score (11.1 ± 7.5) than controls (5.4 ± 4.1 , $p=0.010$) and a higher GDS score (0.77 ± 0.47) than HCV (0.46 ± 0.34 , $p=0.036$), HIV (0.45 ± 0.36 , $p=0.008$) and controls (0.30 ± 0.29 , $p=0.001$). Coinfection was associated with worse scores in attention working memory ($p=0.007$), executive function ($p=0.01$), fine motor function ($p=0.011$), verbal learning/memory ($p<0.001$) and visual learning/memory ($p<0.001$) compared to controls. Within the HCV group, viral load was associated with lower attention, executive function and information processing speed and positively with GDS.

Conclusions: Coinfection significantly increased the risk of cognitive impairment in subjects with controlled HIV viral loads. In HCV monoinfected but not coinfecting subjects, HCV viral load correlated with worsening GDS, suggesting different pathways for neuropsychological impairment.

INTRODUCTION

Hepatitis C virus (HCV) has become a major cause of morbidity and mortality in HIV-infected individuals¹⁻³. It has been reported that 20-30% of HIV-infected individuals are infected with HCV in the United States and worldwide^{4,5}. Since the introduction of antiretroviral treatment (ART) and pegylated-interferon treatment, ART has led to a significant decrease in HIV-associated disease, but the development of cirrhosis in HIV+ patients with longstanding HCV infection continues to increase. Although ART has improved the life expectancy of persons with HIV, coinfecting persons survive to at times develop neuropsychological (NP) impairment which can greatly impact their quality of life. Various studies have shown controlled chronic HIV infection can result in neurocognitive dysfunction. Chronic HCV infection has also been associated with neurocognitive dysfunction, even in the absence of advanced liver damage⁶⁻⁸. HIV/HCV coinfection has been found in some studies to be associated with impairment in executive⁹ and psychomotor function¹⁰, as well as overall cognition^{11, 12}. While some reports did not demonstrate cognitive differences between coinfecting and HCV monoinfected subjects, this could be due to the heterogeneous composition of some cohorts, including active HIV infection and various stages of AIDS, drug or alcohol abuse and the prevalence of cirrhosis. Some studies included HIV+ subjects with high viral load or advanced AIDS, who are fortunately now quite uncommon in the era of ART. AIDS, drug or alcohol abuse, alone or in combination, have been related to neurocognitive dysfunction^{13, 14}. To minimize the interfering factors and comorbid conditions and in an effort to clarify the effect of HCV on cognitive dysfunction or combined with controlled HIV infection, the current cohort was enrolled that was: free of substance abuse, without current clinical depression, and with undetectable HIV viral load. We used an extensive neuropsychological battery of tests including a depression scale to obtain a better

understanding of the impact of HCV among patients with well-controlled HIV who reflect the current use of effective ART treatment.

METHODS

Cohort

This is a cross sectional study of 53 participants recruited from the Gastroenterology clinics at the Veterans Affairs Medical Center, San Francisco (VAMCSF) and the University of California, San Francisco affiliated hospitals who signed written informed consent for protocols that had been approved by the University of California, San Francisco Committee on Human Research. Determining compatibility with the inclusion and exclusion criteria was based on medical record review for HIV and/or HCV-infected subjects and self-report for the controls. All participants were given minimal compensation for participation that was not disclosed on recruitment flyers. In North America, HCV transmission occurs primarily through shared needles during intravenous drug use, blood transfusions prior to 1992, body piercings or tattoos. Among these risk factors, intravenous drug use typically coincides with a history of drug abuse and there is evidence that the use of psychoactive substances can impair cognition, as such patients' histories of past intravenous drug use and other psychoactive substance use were recorded in detail. Inclusion criteria for this study were: males between the ages of 45 and 65 with HCV infection, subjects with HIV/HCV coinfection (HCV genotype 1) or healthy controls. Coinfected subjects were compliant on ART for at least 2 years with undetectable HIV viral load (<50 copies/ml) for 6 months prior to enrollment. Exclusion criteria included: illicit drug use or prescribed opiate pain medications 6 months prior to enrollment; clinical evidence of hepatic cirrhosis (most patients had past liver biopsies without cirrhosis); evidence of any other chronic infectious processes; consumption of >20 grams alcohol per day for the 6 months prior to enrollment; IFN α -based therapy within the previous four years; clinical depression or other

significant psychiatric disease; seizure disorders or history of head injury. Mood disorders and psychiatric exclusionary diagnosis were defined by a clinical interview by the study psychologist (L.A.), using the Structured Clinical Interview for *DSM-IV*¹⁵.

In order to compare HCV mono- and coinfecting subjects with HIV infection, we included 14 HIV monoinfected individuals with undetectable viral loads along with 11 controls from a previous study published in 2010¹⁶. Subjects in the HIV cohort were recruited from the Infectious Disease clinic at the same VAMCSF, using the same inclusion/exclusion criteria with the exception of being HIV infected, on ART, with an undetectable (<50 copies/ml) viral load. All the neuropsychological testing was performed by the same investigator (LA).

Neuropsychological evaluation

Neuropsychological test measures covered 7 domains. The Structured Clinical Interview for *DSM-IV*¹⁵ was used to establish a lifetime history of depressive illness and to diagnose exclusionary psychiatric disorders. Participants also completed a self-report depression measure, the Beck Depression Inventory-II (BDI)¹⁷. General intellect (estimated IQ) was assessed using the Information subtest from the Wechsler Adult Intelligence Scale – Third Edition (WAIS-III)¹⁸. Neuropsychological test results were demographically corrected according to educational level, gender, and age based on the normative scoring for each test. All individual test scores were converted to standard T scores.

Global Deficit Score (GDS)

The GDS is a single number representing overall NP test performances. The T scores from each test were converted to a deficit score based on Carey, et al¹⁹. Briefly, $\geq 40T=0$; $39T-35T=1$; $34T-30T=2$; $29T-25T=3$; $24T-20T=4$; $\leq 19T=5$. The mean of the deficit scores from each test was assigned to the participant as GDS. A GDS of 0.5-1 was considered mild impairment. As reported previously, we used a GDS of ≥ 0.5 as neuropsychologically impaired¹⁶.

Statistical analysis

Demographic data were analyzed using non-parametric statistical analyses (Pearson's Chi-squared test) for categorical data and the rates of significant cognitive impairment across groups. One-way analyses of variance (ANOVA) were used for continuous data. Since education and IQ showed differences, they were included as covariates in the analyses of BDI, GDS and all NP tests in the multivariate analysis of variance (MANOVA). A Tukey's posthoc test was used to compare group differences after MANOVA analysis. Pairwise comparisons of group means were achieved using Student's two sample t test for unequal variances (Welch's t test) with p values adjusted using Benjamini and Hochberg's correction for multiple comparisons²⁰ where necessary. Correlations of neuropsychological domains and GDS with plasma HCV RNA levels were analyzed using Spearman's rank correlation coefficient due to the distribution nature of the data. The correlation between GDS and BDI was also analyzed using Spearman's correlation. All tests were performed with R v2.13.1²¹.

RESULTS

Study Population

We enrolled 19 HCV monoinfected individuals (HCV), treatment naïve except for 2 treatment failures; 17 HCV-infected individuals with controlled HIV-1 infection (Co) and 17 age, education and ethnicity-matched controls (C). Fourteen HIV-infected subjects with undetectable HIV viral load (HIV) and 11 controls from a previous study^{16, 22} were also included for comparison purposes (Table 1). There was no significant difference in HCV plasma viral load between HIV/HCV coinfection and HCV monoinfection ($p=0.31$). Also, there was no significant difference in the mean age of the different groups, while the mean education level of controls was about 2-2.5 years higher than participants with HCV ($p=0.011$), coinfection ($p=0.013$) and HIV ($p=0.012$) (Table 1). IQ was lower in HIV/HCV coinfecting subjects than controls ($p=0.004$) and HIV monoinfected subjects ($p=0.025$) after adjusting education. HCV monoinfected subjects had lower IQ than controls and HIV monoinfected individuals, but this was not statistically

significant ($p=0.098$ and 0.260 , respectively) after adjusting for education. All HIV-infected participants were on ART¹⁶ for over 2 years. All HIV-infected and HIV/HCV coinfecting participants had undetectable plasma HIV viral load at the time of participation (<50 copies/ml). Ethnicity was not a significant variable ($\chi^2 =6.84$, p value= 0.654). No subjects with known cirrhosis were included.

We evaluated participants in the HCV cohort to determine whether exposure to drugs of abuse coincided with lower NP test results. In the HCV group, 63% (12/19) of the participants had a history of drug abuse, while 71% (12/17) of the coinfecting also had abused drugs. A possible relationship between drug abuse and cognition in either of the mono- or coinfecting groups in this study was examined using a Fisher's exact test and was found not to be significant among either HCV monoinfected ($p=0.4$) or coinfecting ($p=1$) subjects. The controls in the HCV cohort did not report any history of drug abuse. For the HIV cohort, a separate drug abuse history, apart from that collected for compliance with the exclusion criteria, was not obtained and is a limitation of this study.

Neuropsychological Findings

Since depressive symptoms may still exist in the HCV-infected patients, we used the Beck Depression Index (BDI), a self-report questionnaire, as a screening tool for perceived depression not diagnosed clinically. Coinfecting subjects were found to have more depressive symptoms by BDI (11.1 ± 7.5) than controls (5.4 ± 4.1 , $p=0.011$) (Fig. 1A) and HCV monoinfected subjects (6.7 ± 6.0 , $p=0.049$), even though no subject carried a clinical diagnosis of depression.

A summary of all NP tests measured in the study was represented by a global deficit score which reflects the overall cognitive status of the participants. HIV/HCV coinfection had a worse GDS score (0.77 ± 0.74) than HCV monoinfection (0.46 ± 0.34 , $p=0.015$), HIV monoinfection (0.45 ± 0.36 , $p=0.008$) or controls (0.30 ± 0.29 , $p<0.001$) (Fig. 1B). The mean GDS of 0.77 for HIV/HCV puts the coinfecting individuals in the mild cognitive impairment range ($0.5-1.0$)¹⁹. The

rates of impairment based on GDS were higher in coinfection (65%) than HCV mono-infection (42%), HIV mono-infection (29%) and controls (18%). While this difference was not statistically significant among coinfection, HIV mono-infection or HCV mono-infection ($\chi^2 = 4.2$, $p = 0.12$), coinfection did have a higher rate than controls ($\chi^2 = 8.2$, $p = 0.004$). There was no correlation found between GDS and BDI in HCV-infected individuals (Spearman's correlation, $\rho = 0.13$, $p = 0.45$) suggesting that depression did not influence GDS. Controls from the HIV and HCV cohorts were used in GDS analysis, while for depression analysis only controls from HCV cohort were used since depression analysis was not done on the HIV cohort.

Although the tests were grouped into domains, individual NP tests showed significant differences among groups after adjusting for education and IQ (Table 2). Lower scores were found in Digit Span and Brown-Peterson tests in HIV/HCV coinfecting subjects indicating impairment in attention and short-term memory. When considering the domain, subjects with HIV/HCV coinfection demonstrated lower performance in attention working memory compared to controls ($p = 0.006$) (Fig. 2). Impairment in Symbol Digit Written test in HIV/HCV coinfection and not in the Symbol Digit Oral test indicates malfunction of psychomotor ability though the Information processing speed domain did not show significant difference (Table 2). Although the Stroop Color and Word test showed higher performance in HIV than C, HCV and coinfection, when considering all 4 tests in the executive function domain, coinfection had lower performance than controls in general ($p = 0.026$) (Fig. 2). In the Grooved pegboard test, the non-dominant hand performed poorer in coinfection than controls ($p = 0.035$). Fine motor function as a domain was impaired in coinfecting subjects than controls ($p = 0.013$). In Brief Visuospatial Memory Test (BVMT) and California Verbal Learning Tests (CVLT), coinfection showed significant impairment in visual learning and memory ($p < 0.001$) and verbal learning and memory ($p < 0.001$) than controls (Fig. 2 and Table 2). Despite undetectable HIV viral loads in both, HIV/HCV coinfecting individuals showed lower ability on fine motor function ($p < 0.001$), visual

learning/memory ($p < 0.001$) and verbal learning/memory ($p = 0.001$) than HIV monoinfected individuals (Fig. 2). HIV/HCV coinfection showed an overall decrease in most of the domains tested (see **Figure S1, Supplemental Digital Content**, <http://links.lww.com/QAI/A369>). Subtle deficits can be seen in verbal learning/memory in coinfecting patients with T scores nearly 1 SD lower than the population mean (see **Figure S1, Supplemental Digital Content**, <http://links.lww.com/QAI/A369>). The visual learning/memory domain showed a moderate deficit in coinfection of almost 2SDs below the mean (mean T score = 30.9 ± 10.0).

While the HCV group did not cross the threshold of cognitive impairment ($GDS \geq 0.5$), HCV plasma viral load was negatively correlated with attention, executive function, and information processing speed in HCV mono-infection (Fig. 3A). These relationships were not observed in coinfecting subjects where HCV viral load did not correlate with cognitive performance. The same respective outcomes for HCV mono- and coinfecting subjects were found when T scores were switched with GDS as a measure of overall cognition (Fig. 3B). Again, only HCV viral load in the context of mono-infection was related to poorer cognitive performance.

DISCUSSION

Over the last decade, numerous studies have assessed the impact of HCV mono-infection and HIV/HCV coinfection on cognition. Overall, results from these studies have been inconclusive with some indicating greater cognitive impairment in coinfecting individuals while other studies fail to detect significant difference between mono- and coinfection¹¹. Potentially there are multiple reasons for this disparity including cohort composition, utilization of different neuropsychological assessments and subtlety of the cognitive dysfunction related to HCV infection. For this cross-sectional study, males under stable medical care who were not abusing drugs were assessed for neuropsychological deficits in seven domains and evaluated for subclinical depression. The study was designed to test for cognitive impairment in coinfecting

subjects whose HIV was controlled as well as to measure cognitive dysfunction in HCV-infected subjects with no current drug or alcohol abuse. In fact, this study represents many American HIV-infected individuals today, who are compliant with their ART and live their lives with undetectable HIV viral loads, as did both coinfecting and HIV monoinfected subjects in this study. Moreover, to remove liver dysfunction as a factor influencing cognition, subjects with cirrhosis were excluded from the study. So while this study comprises a limited number of individuals, its strength lies in a well-characterized cohort with minimal comorbid conditions.

Indications are that coinfection in subjects with undetectable HIV viral loads has at most a subtle impact on cognition. By examining a relatively homogeneous cohort of men all receiving a similar level of medical care, we were able to detect a mild, yet significant impairment in cognition among the coinfecting group. Coinfecting subjects performed poorly on the attention, executive function, fine motor function and visual and verbal learning/memory tests, with significantly lower T scores than either controls or monoinfected subjects. Our results from the male cohort are in contrast to a recent study of coinfecting women, which found no association between viral infection and cognition³². Importantly, in the women's study only a limited number of NP tests were performed to assess two domains: information processing (symbol-digit modalities, Trails part A and B) and executive function (Comalli-Kaplan Stroop test) domains; we also found no differences in these two domains. Our more comprehensive evaluation utilized 20 tests which yielded information for seven domains. Historically, studies on the impact of HIV on neuropsychological function have indicated deficits most consistently in the domain of motor skills, although more recent studies have shown deficits also in attention, executive function and information processing speed¹⁶. Overall, neuropsychological impairment has been reported in a coinfecting cohort with deficits in visual and verbal learning/memory domains, which can interfere with daily life¹². HIV-infected individuals subsequently exposed to HCV also have neurocognitive impairment with abnormal brain metabolites ratios³³. We found both HIV and HCV monoinfected subjects had test results similar to controls in most domains suggesting a

synergistic effect of HIV and HCV in coinfection that is responsible for neuropsychological deficits in the coinfecting population. Previous substance abuse did not correlate with cognitive impairment in the coinfecting group. The majority of these individuals were in the military, and by self-report their substance abuse was related to their youth and since these subjects were all over 45 years old, the impact of previous substance abuse is probably minimal. However, verification of self-report of participants was not done and therefore a limitation of the study.

Our expectation was that lower cognitive scores in HCV mono-infection would be similar to coinfection, likely affecting the same domains but perhaps less severe. Instead, there was a distinctly different pattern in the NP tests which varied with HCV viral load in mono-infection inversely correlating with T scores in three separate domains. While as a group, cognitive scores did not cross the threshold of impairment, these results suggest that greater HCV viral load negatively impacts cognition. HCV viral load has been investigated as an independent factor influencing cognition in HCV mono-infected individuals, but the results have been equivocal. No association between cognition and viral load was detected when HCV-mono-infected subjects were grouped based on their level of fatigue and secondarily evaluated for viral load³⁴. However, when evaluated by Spearman rank coefficient analysis, lower T scores in the attention / working memory domain correlated with higher HCV viral load¹². This was one of the same domains affected in our HCV mono-infected subjects, which also showed a significant correlation with lower T scores. Together these findings imply that HCV viral load may play an important but subtle negative role in cognition, a role which could be better elucidated by experiments specifically designed to assess its impact. The relationship of HCV viral load on NP tests was not detected in coinfecting subjects in this study, suggesting that cognitive impairment observed with coinfection could have a different pathogenesis from that in mono-infection. Some studies showed impairment in attention, concentration, psychomotor speed in HCV infection independent of coinfection¹¹. The mechanisms for NP impairment in HCV infection are still not well elucidated and may be related to direct HCV viral toxicity, as

replicable forms of HCV virus have been detected in autopsy brains^{35, 36}. Brain MRS studies in HCV infection have also demonstrated inflammation in the brain³⁷. HCV has been shown to induce microglia activation³⁸. Brain levels of MCP-1, TNF α , and soluble TNF receptor were found higher in HCV-infected individuals¹². These observations suggest that HCV is neurotoxic although whether the mechanism is direct versus indirect is unknown.

Depression has also been reported to be more severe in coinfection than monoinfection⁶. We found the depression scores in coinfection were slightly higher than controls and HCV monoinfection. Elevated BDI scores indicated that coinfecting individuals experienced more symptoms of depression but did not meet a clinical depression diagnosis. Importantly, BDI scores did not correlate with neuropsychological measures or GDS indicating that depression was not responsible for neurocognitive deficits.

Whether coinfection constitutes a legitimate risk factor for cognition remains to be demonstrated unambiguously. This targeted study indicates that coinfection in males is sufficient to push this group over the threshold into mild impairment and high viral load in HCV monoinfection may impact cognition.

ACKNOWLEDGEMENTS

We thank our patients for their participation and Dorthe Welch RN for recruitment.

REFERENCES

1. Monto A, Schooley RT, Lai JC, et al. Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. *Am J Gastroenterol*. 2010;105:989-1004; quiz 1988, 1005.
2. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. *AIDS*. 2010;24:1537-1548.
3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis*. 2005;5:558-567.

4. Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. *Clin Infect Dis*. 2002;34:831-837.
5. Cargill VA. HIV/hepatitis C virus co-infection: its human face. *AIDS*. 2005;19 Suppl 3:S1-2.
6. Clifford DB, Evans SR, Yang Y, et al. The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. *AIDS*. 2005;19 Suppl 3:S64-71.
7. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. *Hepatology*. 2002;35:433-439.
8. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. *Hepatology*. 2002;35:440-446.
9. Ryan EL, Morgello S, Isaacs K, et al. Neuropsychiatric impact of hepatitis C on advanced HIV. *Neurology*. 2004;62:957-962.
10. von Giesen HJ, Heintges T, Abbasi-Boroudjeni N, et al. Psychomotor slowing in hepatitis C and HIV infection. *J Acquir Immune Defic Syndr*. 2004;35:131-137.
11. Perry W, Carlson MD, Barakat F, et al. Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. *AIDS*. 2005;19 Suppl 3:S79-84.
12. Letendre SL, Cherner M, Ellis RJ, et al. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. *AIDS*. 2005;19 Suppl 3:S72-78.
13. Devlin KN, Gongvatana A, Clark US, et al. Neurocognitive effects of HIV, hepatitis C, and substance use history. *J Int Neuropsychol Soc*. 2012;18:68-78.
14. Persidsky Y, Ho W, Ramirez SH, et al. HIV-1 infection and alcohol abuse: neurocognitive impairment, mechanisms of neurodegeneration and therapeutic interventions. *Brain Behav Immun*. 2011;25 Suppl 1:S61-70.

15. First M, Spitzer R, Williams J, et al. *Structured Clinical Interview for DSM-IV (SCID-I; Patient Version ed.)*. New York: New York State Psychiatric Institute, Biometrics Research; 1996.
16. Sun B, Abadjian L, Rempel H, et al. Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection. *J Neurovirol*. 2010;16:115-124.
17. Beck AT, Steer RA, Brown GK. *Manual for the Beck Depression Inventory-II*. San Antonio, TX: Psychological Corporation; 1996.
18. Wechsler D. *Wechsler Adult Intelligence Scale*. 3rd ed. San Antonio, TX: The Psychological Corporation; 1997.
19. Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. *J Clin Exp Neuropsychol*. 2004;26:307-319.
20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society, Series B (Methodological)*. 1995;57:125-133.
21. Ihaka R, Gentleman R. R: A Language for Data Analysis and Graphics. *Journal of Computational and Graphical Statistics*. 1996;5:299-314.
22. Rempel H, Sun B, Calosing C, et al. Interferon-alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection. *AIDS*. 2010;24:1415-1423.
23. Struss DT, Stethem LL, Poirier CA. Comparison of three tests of attention and rapid information processing across six age groups. *The Clinical Neuropsychologist*. 1987;1:139-152.
24. Smith A. *Symbol Digit Modalities Test (SDMT) Manual*. Revised ed. Los Angeles, CA: Western Psychological Services; 1982.
25. Golden CJ. *Stroop Color and Word Test*. Chicago, IL: Stoelting; 1978.

26. Heaton RK, Chelune GJ, Talley JL, et al. *Wisconsin Card Sorting Test (WCST) manual*. Revised and expanded ed. Odessa, FL: Psychological Assessment Resources; 1993.
27. Klove H. Clinical neuropsychology. In: *The medical clinics of North America*. Edited by FM F. New York: Saunders; 1963.
28. Halstead W. *Brain and Intelligence* Chicago: University of Chicago Press; 1947.
29. Benton AL, Hamsher K, Sivan AB. *Multilingual Aphasia Examination* 3rd ed. Iowa City, IA: AJA Associates; 1983.
30. Benedict RH. *Brief Visuospatial Memory Test- Revised (BVRT-R)*. . Odessa, FL: Psychological Assessment Resources, Inc; 1997.
31. Delis DC, Kaplan E, Kramer JH, et al. *California Verbal Learning Test – Second Edition (CVLT-II)*. San Antonio, TX: The Psychological Corporation; 1987.
32. Crystal H, Kleyman I, Anastos K, et al. Effects of hepatitis C and HIV on cognition in women: data from the Women's Interagency HIV Study. *J Acquir Immune Defic Syndr*. 2012;59:149-154.
33. Winston A, Garvey L, Scotney E, et al. Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals? *J Viral Hepat*. 2010;17:419-426.
34. McAndrews MP, Farcnik K, Carlen P, et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. *Hepatology*. 2005;41:801-808.
35. Wilkinson J, Radkowski M, Laskus T. Hepatitis C virus neuroinvasion: identification of infected cells. *J Virol*. 2009;83:1312-1319.
36. Letendre S, Paulino AD, Rockenstein E, et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. *J Infect Dis*. 2007;196:361-370.
37. Forton DM, Hamilton G, Allsop JM, et al. Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study. *J Hepatol*. 2008;49:316-322.

38. Grover VP, Pavese N, Koh SB, et al. Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation. *J Viral Hepat.* 2012;19:e89-96.

ACCEPTED

FIGURE LEGENDS

Figure 1. Group comparisons of depression and global deficit score. A) Comparisons of BDI scores for controls HCV and HIV/HCV infections. Controls were recruited in the HCV cohort. B) Comparisons of controls, HCV mono-infection, HIV/HCV coinfection and HIV mono-infection of GDS scores. Controls were used from both HCV and HIV cohorts. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ using MANOVA with education and IQ adjusted. BDI=Beck depression inventory-II score. GDS=global deficit score. C=controls, HCV=HCV mono-infection, Co=HIV/HCV coinfection.

Figure 2 Group comparisons of significant neuropsychological domains. MANOVA analyses with education and IQ adjusted were used to compare group means. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. C=controls, HCV=HCV mono-infection, Co=HIV/HCV coinfection, HIV=HIV mono-infection.

Figure 3. Correlations of plasma HCV viral load with neuropsychological data. Spearman's rank correlation was used to compute the correlations. HCV RNA was shown as logarithm base 2 transformed. HCV=HCV mono-infection, Co=HIV/HCV coinfection. GDS=global deficit score. A) HCV viral load negatively correlated with attention/working memory, executive function and information processing speed. Lower T scores are evidence of poorer performance. As HCV plasma load increases, T scores decrease in mono-infection only. B) In mono-infection, HCV viral load significantly correlated with global deficit scores. Higher GDS indicates poorer cognition.

Figure S1. Mean T scores of neuropsychological domains. Mean denotes the population mean T score level is 50 and 1 SD denotes 1 standard deviation from the mean. Although most of the T scores for the domains were within 1 SD range, the mean T scores for coinfection were on the lower end for almost all of the domains. Global was the average of all domains. Connected lines

only demonstrate groups, no relationship between domains was implicated. C=controls, HCV=HCV mono-infection, Co=HIV/HCV co-infection, HIV=HIV mono-infection.

ACCEPTED

Table 1. Participant demographics, clinical and laboratory characteristics

	C	HCV	Co	HIV	P values
N	28	19	17	14	
Age (yr)	53.2 (6.0)	56.6 (4.5)	54.5 (5.2)	51.6 (7.2)	0.081
Education (yr)	15.4 (2.3)	13.1 (2.2)	13.4 (2.1)	13.6 (1.2)	0.001 ^a
Ethnicity					0.868
Asian	2	0	0	0	
African.American	5	6	6	2	
Caucasian	19	11	10	11	
Hispanic	2	2	1	1	
Estimated IQ (T score)	57.2 (9.1)	51.7 (8.6)	49.0 (8.6)	56.9 (8.1)	0.010 ^b
Global deficit score	0.30 (0.29)	0.46 (0.34)	0.77 (0.47)	0.45 (0.36)	<0.001 ^c
Beck Depression Inventory Score	5.4 (4.1)	6.7 (6.0)	11.1 (7.5)	NA	0.010 ^d
HCV RNA (log ₁₀ IU/mL)	NA	5.9 (0.7)	6.2 (0.5)	NA	0.305
HIV RNA (log ₁₀ RNA/mL)	NA	NA	UD	UD	NA
CD4 count (cells/ul)	NA	NA	501 (243)	516 (261)	0.890

Note: Values are presented as mean (SD) except for N and ethnicity which were the number of individuals and drug abuse history which is percent. All participants were male. NA: not applicable or not available. C=controls, HCV=HCV mono-infection, Co=HIV/HCV co-infection, HIV=HIV mono-infection. UD=undetectable. P values stand for one-way ANOVA test except ethnicity (Chi-squared test). MANOVA was used in GDS and BDI with education and IQ as covariates. P values for HCV RNA and CD4 count were from Student's t tests.

a: mean years of education of HCV, Co and HIV were lower than controls, no difference between them.

b: mean IQ of HCV and Co were lower than C, mean IQ of Co was lower than HIV.

c: mean GDS score of Co was higher than C after adjusting for education and IQ, Tukey HSD posthoc test $p < 0.001$.

d: mean BDI of Co was higher than C and HCV after adjusting for education and IQ, Tukey HSD posthoc test $p = 0.010$ and 0.049 , respectively.



ACCEPTED

Table 2. Neuropsychological test results


Domain / Test Name	Mean (SD)				P values
	C	HCV	Co	HIV	
Attention working memory					
WAIS-III Digit Span ¹⁸	53.2 (10.4)	46.2 (7.9)	45.6 (9.3)	50.4 (9.1)	0.005
Brown Peterson 18 ²³	53.7 (10.0)	45.3 (11.3)	45.2 (12.2)	39.1 (17.3)	0.004
Brown Peterson 36 ²³	55.1 (9.1)	44.8 (13.1)	49.0 (6.8)	43.9 (11.2)	0.001
Information processing speed					
Symbol Digit Oral ²⁴	48.8 (11.6)	45.6 (10.0)	43.2 (10.8)	48.6 (11.5)	0.126
Symbol Digit Written ²⁴	50.2 (11.5)	43.8 (10.3)	43.2 (9.7)	46.9 (8.3)	0.026
Stroop Word ²⁵	47.3 (7.7)	45.9 (7.7)	46.5 (8.1)	NA	0.880
Stroop Color ²⁵	43.2 (9.9)	42.9 (8.3)	43.0 (5.3)	45.4 (7.1)	0.717
Executive function					
Stroop Color and Word ²⁵	46.4 (6.9)	43.3 (7.3)	43.1 (8.3)	52.6 (7.4)	<0.001
Stroop Interference ²⁵	49.9 (5.9)	48.4 (5.3)	47.5 (6.0)	NA	0.136
WCST total errors ²⁶	43.2 (9.1)	41.1 (10.5)	35.1 (8.3)	39.2 (12.8)	0.075
WCST perseveration ²⁶	46.0 (12.6)	47.7 (8.3)	39.9 (7.6)	42.0 (11.2)	0.123
Fine motor skills					
Grooved Pegboard Dominant Hand ²⁷	50.3 (14.5)	50.2 (11.8)	45.2 (8.6)	56.3 (12.8)	0.069
Grooved Pegboard Non-Dominant Hand ²⁷	51.2 (11.9)	49.2 (13.7)	43.1 (7.8)	57.8 (10.5)	0.002
Finger Tapping Dominant Hand ²⁸	44.3 (9.0)	45.6 (8.4)	39.4 (9.4)	NA	0.115

Finger Tapping Non-Dominant Hand ²⁸	42.0 (9.5)	45.3 (7.6)	41.2 (7.1)	NA	0.107
Verbal fluency					
COWA Test ²⁹	47.4 (9.2)	47.6 (8.1)	46.1 (8.6)	49.9 (8.4)	0.663
Visual learning/memory					
BVMT trials 1-3 ³⁰	44.9 (13.5)	36.8 (12.0)	29.8 (9.3)	44.1 (14.0)	<0.001
BVMT delay ³⁰	46.0 (12.8)	42.5 (14.4)	31.9 (11.4)	47.6 (11.7)	<0.001
Verbal learning/ memory					
CVLT total 1-5 ³¹	55.0 (10.9)	47.1 (9.2)	39.8 (11.6)	53.9 (8.8)	<0.001
CVLT Long Delay Free Recall ³¹	52.3 (10.6)	47.4 (8.2)	43.2 (6.6)	52.5 (6.4)	0.001


Note: Values are presented as mean (SD) of T scores for all tests. C=controls, HCV=HCV monoinfection, Co=HIV/HCV coinfection, HIV=HIV monoinfection. NA=not available. WAIS=Wechsler Adult Intelligence Scale; WCST= Wisconsin Card Sorting Test); COWA= Controlled Oral Word Association; BVMT= Brief Visuospatial Memory Test; CVLT= California Verbal Learning Test. P values are of MANOVA with education and IQ as covariate.



ACCEPTED



ACCEPTED



ACCEPTED